Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials
PLEASANTON, Calif. and NASHVILLE, Tenn., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations. SCRI is adopting Veeva Clinical Platform to unify its contract research organization (CRO) and site management organization (SMO) on a single platform for seamless data flow across clinical teams and research sites.
'We are thrilled to advance our clinical trials by integrating Veeva Clinical Platform into our digital toolkit,' said SCRI chief information and digital officer Yazhene Krishnaraj. 'This strategic collaboration empowers our clinical teams to deliver groundbreaking therapies to patients with enhanced precision and speed.'
Veeva Clinical Platform will enable SCRI to simplify and standardize trial processes and information flow, improving how investigators and clinical teams work together and share data. With a connected foundation for clinical research, SCRI will be able to automate key processes and provide a streamlined experience for its sites.
'We're excited to work closely with SCRI to drive innovation in oncology research,' said Jim Reilly, president of Veeva Development Cloud. 'In a first-of-a-kind partnership, Veeva Clinical Platform will serve as SCRI's clinical trial foundation for its CRO and SMO. By standardizing operations on one platform, we can support SCRI in delivering faster and more cost-effective trials.'
About Veeva Clinical Platform
Veeva Clinical Platform is a complete and connected platform across clinical operations and data applications. This end-to-end platform includes CTMS, EDC, clinical workbench (CDB), RTSM, eCOA, eTMF, Site Connect, Study Training, and more. Connected products streamline clinical trials from study start-up to close and automate a connected data flow. To learn more about Veeva Clinical Platform, visit veeva.com/VeevaClinicalPlatform.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI's research network brings together more than 1,300 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S. Visit SCRI.com to learn more.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's strategic collaboration with SCRI and the expected results or benefits from such collaboration. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.
View original content to download multimedia: https://www.prnewswire.com/news-releases/veeva-and-sarah-cannon-research-institute-form-strategic-collaboration-to-advance-oncology-clinical-trials-302472592.html
SOURCE Veeva Systems
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
24 minutes ago
- Business Insider
Canaccord Genuity Sticks to Its Buy Rating for Eve Holding (EVEX)
Canaccord Genuity analyst Austin Moeller maintained a Buy rating on Eve Holding today and set a price target of $6.75. The company's shares closed today at $4.26. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Moeller covers the Industrials sector, focusing on stocks such as BlackSky Technology, Joby Aviation, and Archer Aviation. According to TipRanks, Moeller has an average return of 7.8% and a 42.36% success rate on recommended stocks. In addition to Canaccord Genuity, Eve Holding also received a Buy from Cantor Fitzgerald's Andres Sheppard in a report issued on August 7. However, on August 12, BTIG initiated coverage with a Hold rating on Eve Holding (NYSE: EVEX). The company has a one-year high of $7.70 and a one-year low of $2.37. Currently, Eve Holding has an average volume of 556.2K.
Business Insider
24 minutes ago
- Business Insider
US Tiger Securities Sticks to Its Buy Rating for XPeng, Inc. ADR (XPEV)
In a report released today, Bo Pei CFA from US Tiger Securities reiterated a Buy rating on XPeng, Inc. ADR, with a price target of $28.00. The company's shares closed today at $20.74. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Pei CFA is ranked #9697 out of 9921 analysts. In addition to US Tiger Securities, XPeng, Inc. ADR also received a Buy from Bank of America Securities's Ming-Hsun Lee in a report issued today. However, on August 11, Bernstein maintained a Hold rating on XPeng, Inc. ADR (NYSE: XPEV). The company has a one-year high of $27.16 and a one-year low of $6.65. Currently, XPeng, Inc. ADR has an average volume of 6.99M.
Yahoo
2 hours ago
- Yahoo
This Quantum Computing Stock Just Made an AI Breakthrough
Key Points The unique capabilities of quantum computers could accelerate the evolution of artificial intelligence (AI). In a bid to advance the AI field, D-Wave Quantum developed a new tool kit integrating AI with quantum devices. Sales of D-Wave's tech delivered $18.1 million, a 289% year-over-year increase through the first half of 2025. 10 stocks we like better than D-Wave Quantum › Artificial intelligence (AI) is a hot sector with forecasts predicting the market to grow from $244 billion in 2025 to over $800 billion by 2030. This astounding growth could be supercharged by the advent of quantum computers. Quantum machines possess the ability to complete intricate calculations that surpass the capacities of classic computers. Marrying quantum devices with AI opens up new possibilities not attainable today. That's what makes the release of AI tools by D-Wave Quantum (NYSE: QBTS) a significant development. The tool set enables integration with D-Wave's quantum computers. Does this melding of AI and quantum tech suggest D-Wave stock is worth investing in? To assess the opportunity, let's look into what the company is doing and whether now is the time to buy shares in D-Wave. Details of D-Wave's new AI features On Aug. 4, D-Wave rolled out new tools allowing AI software developers to experiment with its quantum computer processors. This tool kit integrates the company's quantum systems with PyTorch, a framework for building AI models that has become a leader in the space. D-Wave's tools provide a PyTorch neural network module, enabling the development and training of AI models using a quantum computer. Today, these models require massive computational power and energy. As a result, the cost to build AI is escalating. According to Dr. Alan Baratz, CEO of D-Wave, "Quantum computing's integration with AI and machine learning could offer scalable, energy-efficient solutions to address these issues and potentially offer enhanced AI capabilities." The company is already working with customers to advance the use of AI with quantum machines. For instance, it's partnering with the pharmaceutical division of Japan Tobacco to combine quantum systems and AI in the drug-discovery process. The impact of D-Wave's tech on financial performance Delivering the ability of quantum computers to assist with AI development is an impressive milestone. But how have D-Wave's technological advances helped the company? Through the first half of 2025, D-Wave's sales have skyrocketed 289% year over year to $18.1 million. Its Japan Tobacco partnership is an example of broader customer demand, as orders in the Asia-Pacific region have grown 83% over the past 12 months. Clients in the area seek to apply D-Wave's quantum tech to AI and other business challenges. As a result, the company is holding its first quantum computing conference in Tokyo on Sept. 17. Moreover, D-Wave's gross margin ticked up to 63.8% in the second quarter from 63.6% in the prior year. You want to see gross margin steadily rise, as it means the company is improving cost management and thereby growing gross profit, which improved 42% year over year for D-Wave to $2 million off $3.1 million in Q2 sales. However, D-Wave doesn't operate a profitable business. Its Q2 loss from operations reached $26.5 million, up from a loss of $18.8 million in 2024, as research and development costs grew more than 50% year over year to $12.7 million. The increase in D-Wave's expenses are to be expected, since developing cutting-edge technology is not easy -- or cheap. In fact, many tech companies operate at a loss for years as they pour earnings into building up their businesses. So D-Wave's situation is not uncommon. In addition, the company has amassed a sizable war chest of $819.3 million in cash and equivalents at the end of Q2. This brought Q2 total assets to $843.6 million versus total liabilities of $149.3 million. The solid balance sheet funds operations in the short term while the company ramps up sales and seeks strategic acquisitions. Evaluating whether to invest in D-Wave stock Do these factors mean now is the time to invest in D-Wave stock? One consideration is share-price valuation. This can be assessed using the price-to-sales (P/S) ratio, which measures how much investors are willing to pay for every dollar of revenue generated over the trailing 12 months. The chart shows D-Wave's P/S multiple has gone up since it plunged in April along with the broader stock market due to President Trump's aggressive tariff approach. As of Aug. 15, it's near previous peaks, suggesting D-Wave shares are pricey. The other consideration is that quantum computers suffer challenges that prevent them from becoming scalable and cost effective. These devices use atomic particles to perform computations, but the particles are sensitive to the slightest environmental disruption, such as vibrations or temperature fluctuations. D-Wave is working to overcome these challenges but so are its many competitors, and it could take years to solve the issues. As a result, investing in D-Wave is only for those with a high risk tolerance. A judicious approach is to wait for D-Wave's share price to drop before deciding to buy. Should you buy stock in D-Wave Quantum right now? Before you buy stock in D-Wave Quantum, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and D-Wave Quantum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This Quantum Computing Stock Just Made an AI Breakthrough was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
